We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
Germany-based pharmaceutical company, which has been developing products and forms of therapy in gastroenterology and hepatology, as well as the fields themselves, has contracted OCT Clinical to run a Ph3 gastroenterology study. The clinical trial will take place in Europe and Canada.
This is a double-blind, double-dummy, randomized, parallel-group, non-inferiority phase III trial on the efficacy and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets for induction of histological remission in adults with eosinophilic esophagitis.
The recruitment target for the entire global study in all countries is 242 randomized male or female patients, between 18 and 75 years of age with active eosinophilic esophagitis.The plan is to involve approximately 35 sites in several European countries, with Canada as a further option.
Within this project, the OCT Clinical team is responsible for activities at four research sites in Eastern Europe. For more information on OCT’s CRO services, click here.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
